Day One BiopharmaceuticalsDAWN 12 Days Payable is 71.36 as of Dec. 2025, which is 48% below its 10-year median of 138.01. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 708 Biotechnology companies, Day One Biopharmaceuticals ranks worse than 55.93% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Day One Biopharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Days Payable falls into.
Day One Biopharmaceuticals Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals (DAWN) has a Days Payable of 71.36 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Day One Biopharmaceuticals and its competitors. This is 48% below median its historical median of 138.01. Over the past decade, Day One Biopharmaceuticals' Days Payable has ranged from 74.18 to 201.83. According to the industry distribution chart, Day One Biopharmaceuticals ranks #396 out of 708 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Day One Biopharmaceuticals' Days Payable too high?
Day One Biopharmaceuticals' current Days Payable of 71.36 is 48% below median its 10-year median of 138.01. Over the past 10 years, this metric has ranged from a low of 74.18 to a high of 201.83. The Biotechnology industry median Days Payable is 113.56. Day One Biopharmaceuticals' value of 71.36 is 37.2% below this industry median. Based on the distribution chart, Day One Biopharmaceuticals ranks #396 out of 708 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Days Payable compare to TYRA and DFTX?
According to the Biotechnology industry distribution chart, Day One Biopharmaceuticals ranks #396 out of 708 companies for Days Payable. This places Day One Biopharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. Day One Biopharmaceuticals' value of 71.36 is 37.2% below this benchmark. Historically, Day One Biopharmaceuticals' own Days Payable has ranged from 74.18 to 201.83 over the past decade. While the company's 10-year median is 138.01 vs. the industry median of 113.56, Day One Biopharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Day One Biopharmaceuticals's current Days Payable of 71.36 is 37.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Day One Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Day One Biopharmaceuticals's current Days Payable is 71.36, which is 48% below median its own 10-year median of 138.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Days Payable of 71.36. The current Days Payable is 71.36, which is 48% below median its 10-year median of 138.01 and 37.2% below the Biotechnology industry median of 113.56. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Days Payable is 71.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
